Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial.

ABSTRACT:

Importance

The effect of metformin on reducing symptom duration among outpatient adults with COVID-19 has not been studied.

Objective

To assess metformin compared with placebo for symptom resolution during acute infection with SARS-CoV-2.

Design, setting, and participants

The Accelerating COVID-19 Therapeutic Interventions and Vaccines platform evaluated repurposed medications for mild to moderate COVID-19. Between September 19, 2023, and May 1, 2024, participants 30 years or older with confirmed SARS-CoV-2 infection and 2 or more COVID-19 symptoms for 7 days or less were included at 90 US sites.

Interventions

Participants were randomized to receive metformin (titrated to 1500 mg, daily) or placebo for 14 days.

Main outcomes and measures

The primary outc

SUBMITTER: Bramante CT 

PROVIDER: S-EPMC12261116 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature